Praxis cites doubts over late-stage trial success: Wedbush downgrades (update)
Praxis Precision Medicines (PRAX) stock falls amid concerns over success in its late-stage trial for lead asset ulixacaltamide in essential tremor. Read more here.
Praxis shares slump as committee says drug trial unlikely to meet main goal
Praxis Precision Medicines said an independent committee had recommended stopping a late-stage trial of an experimental drug for a movement disorder as it was unlikely to meet the main goal, sending ...
Market Whales and Their Recent Bets on PRAX Options
2 market experts have recently issued ratings for this stock, with a consensus target price of $130.5.
Praxis Precision Medicines to Participate in Five Upcoming Investor Conferences
Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders ...
Finanznachrichten10d
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BOSTON, March 04, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (Nasdaq: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies ...